2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

715 A multicenter phase 1 trial of revumenib as maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A-rearranged or NPM1-mutated acute leukemia

Brian John Ball, MD, MS, Mahasweta Gooptu, MD2, Sally Mokhtari, PhD3, Dongyun Yang, PhD4, Ling Li, PhD5, Christopher S Hourigan, DM DPhil FRCP6, Robert Zeiser, MD, PhD7, Vaibhav Agrawal, MD8, Paul Koller, MD9, Pamela S. Becker, MD, PhD10, Len Farol11, Yazeed Samara, MD12, Nahid Rashid, MD13, Anthony Selwyn Stein, MD14, Guido Marcucci, MD15, Monzr M. M Al Malki, MD16, Corey Cutler, MD,FRCPC,MPH17, Ryotaro Nakamura, MD18, Ibrahim Aldoss, MD19
1 City of Hope National Medical Center, Duarte, California, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, District of Columbia, United States
7 University of Freiburg Medical Center, Freiburg, Baden-Württemberg, Germany
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 Kaiser Permanente, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 Kaiser Permanente, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States
16 City of Hope National Medical Center, Duarte, California, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 City of Hope National Medical Center, Duarte, California, United States
19 City of Hope National Medical Center, Duarte, California, United States

Allogeneic hematopoietic cell transplant (HCT) is a potentially curative post-remission therapy for acute leukemia (AL). However, patients (pts) with KMT2A rearrangements (KMT2Ar)  or high-risk Nucleophosmin 1 mutations (mNPM1) remain at increased risk for relapse and shorter survival. Revumenib, a first-in-class, oral, potent, and selective inhibitor of the menin-KMT2A interaction, is used for the treatment of R/R AML harboring an mNPM1 or R/R AL with a KMT2Ar in adult and pediatric pts ≥ 1 year. Here, we report findings from the first phase 1 trial evaluating revumenib as post-HCT maintenance in pts with KMT2Ar or high-risk mNPM1 AL after completion of dose escalation.

The primary objective of this trial was to evaluate the safety and tolerability of post-HCT revumenib and determine the recommended phase 2 dose (RP2D). Revumenib was administered orally twice daily in 28-day cycles starting day +50 to +150 post-HCT, for up to 2 years (yrs). Pts were enrolled at a starting dose of 160mg q12h (DL1) with escalation to 270mg q12h (DL2). A de-escalation dose at 110mg q12h (DL-1) was allowed. Dose adjustment for pediatric pts (< 40 kg) or concomitant use of a strong CYP3A4 inhibiting antifungal was permitted.  The primary endpoint was toxicity, graded according to CTCAE v.5.0, and the dose-limiting toxicities (DLTs) were evaluated during the first . Secondary endpoints include survival outcomes, relapse, non-relapse mortality (NRM), acute and chronic graft-vs-host disease (GVHD), feasibility, and measurable residual disease (MRD) clearance by molecular and immunophenotypic methods. Dose escalation/de-escalation followed a Bayesian optimal interval (BOIN) design with a target DLT rate of 0.2. 

For the dose-escalation phase, 18 pts (9 KMT2Ar and 9 mNPM1) received revumenib at two dose levels (DL1: 7 pts, DL2: 11 pts). Median age was 51 yrs (range 19-80 yrs); most were in CR1 pre-transplant (83.3%), and received myeloablative conditioning (61.1%), and 50% received matched unrelated donor grafts. Among KMT2Ar pts (n=9), the majority had AML (n=7) and translocations other than t(9;11) (n=7), consistent with adverse-risk disease per ELN 2022.  Among mNPM1 pts (n=9), high-risk features included molecular MRD detected pre-transplant by NPM1 qPCR in CR1 or CR2 (n=6), co-occurring FLT3-ITD mutation (n=2), and CR2 or later MRD-negative (n=1).  Median time from HCT to revumenib initiation was 84 days (range 50-149 days).

The most common ≥ grade (G) 3 treatment-emergent adverse events (TEAE) were hematologic: G3 neutropenia (DL1, n=3; DL2, n=6), thrombocytopenia (DL2, n=8), anemia (DL1, n=1, DL2, n=3); G4  were limited to DL2 (one neutropenia and one thrombocytopenia). Hematologic toxicities were reversible and managed with growth factors and dose interruption/reduction. The most common non-hematologic G3 TEAEs included QT interval prolongation (DL1, n=1, DL2, n=1) and nausea/emesis (DL2, n=3). Three pts were not DLT-evaluable: 2 received ≤75% of the specified cycle 1 dose due to GVHD, and 1 inadvertently took less than the prescribed revumenib dose. Toxicity-related dose reductions occurred in 3 pts at DL2. Four pts discontinued treatment: 2 due to a treatment-related toxicity (one at each DL) and 2 for reasons unrelated to toxicity (one at each DL). Fourteen pts are continuing revumenib, including 5 pts beyond 1 year of treatment.

At the median follow-up of 5.1 months (range 0.6-18.3) from revumenib initiation, no relapse, NRM, or G2-4 acute GVHD was observed. All three mNPM1-mutated pts with post-HCT MRD positivity treated at DL1 cleared NPM1 molecular MRD (mMRD) within 1-2 cycles of revumenib.  Correlative analyses, including whole-genome informed ultra-deep molecular MRD testing and human endogenous retrovirus (HERV) activation in AML to further characterize activity, are ongoing.

In this phase 1 trial, post-HCT revumenib demonstrated an acceptable safety profile and was generally well-tolerated in pts with KMT2Ar and high-risk mNPM1 AL. Preliminary results of post-transplant revumenib maintenance suggest durable anti-leukemic activity with mMRD clearance, no relapses observed to date, and sustained MRD negativity exceeding one year in some pts. Rationale for determining the RP2D, including relevant safety and efficacy data, will be presented at ASH. Following RP2D determination, enrollment will continue in dose expansion (NCT06575296).  

Brian John Ball, MD, MS: Geron - Stock (publicly traded); Syndax - Research Funding; Bristol Meyers Squibb - Consultancy (Includes expert testimony)